As 2024 comes to a close, I’ve been reflecting on the incredible path I’ve traveled since founding Blumio eight years ago. Leaving big tech to start a wearable blood pressure company was a leap into the unknown—a decision driven by a belief in the power of technology to transform health outcomes. Since then, my journey has evolved in ways I couldn’t have imagined. When Blumio was acquired by Cardiex two years ago, I transitioned into a public company at the commercial stage—a pivotal shift from building early-stage technology to delivering real-world solutions at scale. This phase has been transformative in more ways than one, not least because it brought me back to my roots in solution selling.
From Big Tech to Biomarkers: Reflections of an Accidental Health Tech Entrepreneur
